Needham & Company Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Copaxone Inequitable Conduct Concluding Arguments; Proof-of-intent Hurdle Considerable
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA) price target of $27.00.
Needham analyst, Ritu Baral, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst, Ritu Baral, said ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
